<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730470</url>
  </required_header>
  <id_info>
    <org_study_id>U3P1287/01</org_study_id>
    <nct_id>NCT00730470</nct_id>
  </id_info>
  <brief_title>Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Open-label, Dose-Finding Study to Assess the Safety and Tolerability of U3-1287 (AMG 888), a Human Monoclonal Antibody Targeting HER3 in Patients With Advanced Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U3 Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U3 Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 clinical study to investigate the safety, pharmacokinetics, and&#xD;
      pharmacodynamics of U3-1287 (AMG 888), a fully human monoclonal antibody targeting the HER3&#xD;
      receptor, in patients with advanced solid tumors. Eligible patients will have disease that is&#xD;
      refractory or resistant to standard treatments or for which no standard therapy exists. The&#xD;
      study will be conducted in two parts; a dose escalation (Part 1) and a dose expansion (Part&#xD;
      2). The hypothesis for this study is that U3-1287 (AMG888) will be safe and well tolerated in&#xD;
      patients with advanced solid tumors and will show initial evidence of anti-tumor activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of U3-1287 (AMG888) in patients with advanced solid tumors</measure>
    <time_frame>Lenth of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate maximum tolerated dose (MTD) of U3-1287(AMG888) when administered intravenously to patients with advanced solid tumors</measure>
    <time_frame>Lenth of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Parameters</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human anti-human antibody profile for U3-1287(AMG888)</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>U3-1287 (AMG888)</intervention_name>
    <description>IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically or cytologically documented advanced solid tumor that is refractory to&#xD;
             standard treatment, for which no standard therapy is available, or the patient refuses&#xD;
             standard therapy.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.&#xD;
&#xD;
          -  Men or women at least 18 years of age&#xD;
&#xD;
          -  Adequate hematologic, cardiac, renal, hepatic, metabolic, and coagulation function&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Presence of untreated or symptomatic brain metastasis.&#xD;
&#xD;
          -  Presence of ascites or pleural effusion requiring chronic medical intervention.&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Concurrent or previous (within 1 week of study day 1) anticoagulation therapy, except&#xD;
             low-dose warfarin (≤ 2 mg/day) or low dose,low molecular weight heparin for&#xD;
             prophylaxis against central venous catheter thrombosis.&#xD;
&#xD;
          -  Recent major surgical procedure or not yet recovered from major surgery&#xD;
&#xD;
          -  Recent participation in clinical drug trials.&#xD;
&#xD;
          -  Participation in other investigational procedures.&#xD;
&#xD;
          -  Unresolved toxicities from prior anti-cancer therapy&#xD;
&#xD;
          -  Patient who is pregnant (e.g. positive human choriogonadotropin [HCG] test) or&#xD;
             nursing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dana Faber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Centre</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram cancer Centre</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>August 7, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>July 28, 2010</last_update_submitted>
  <last_update_submitted_qc>July 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Alan Boyd MD</name_title>
    <organization>U3 Pharma GmbH</organization>
  </responsible_party>
  <keyword>Human Epidermal Growth Factor Receptor 3</keyword>
  <keyword>HER3</keyword>
  <keyword>Heregulin</keyword>
  <keyword>erb B3</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Phase I Clinical Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

